News

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

  • MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety review of the ongoing Phase 3 ASPIRE clinical trial evaluating ivospemin in combination with gemcitabine and nab-Paclitaxel for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The DSMB recommended study continuation without modification, marking the third consecutive positive safety review. The safety database now includes 395 patients, compared to 214 patients on November 29, 2023.
    06/24/2024

Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts

  • Panbela Therapeutics, Inc. (NASDAQ:PBLA – Free Report) – Analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for Panbela Therapeutics in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.07) for the quarter, down from their prior estimate of ($1.28). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Panbela Therapeutics’ current full-year earnings is ($8.38) per share. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($2.07) EPS, Q4 2024 earnings at ($1.98) EPS, FY2024 earnings at ($8.38) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($1.01) EPS. Separately, Roth Mkm reissued a “buy” rating on shares of Panbela Therapeutics in a report on Wednesday, March 27th. Read Our Latest Research Report on Panbela Therapeutics Panbela Therapeutics Stock Performance Shares of PBLA stock opened at $0.44 on Monday. The stock’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $5.94. The firm has a market capitalization of $1.53 million, a PE ratio of 0.00 and a beta of 1.55. Panbela Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $243.06. Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($65.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($24.34) by ($41.56). About Panbela Therapeutics (Get Free Report) Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. Read More Five stocks we like better than Panbela Therapeutics What Are Growth Stocks and Investing in Them MarketBeat Week in Review – 5/13 – 5/17 What is Forex and How Does it Work? Take-Two Interactive Software Offers 2nd Chance for Investors Using the MarketBeat Dividend Tax Calculator Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
    05/20/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Panbela Therapeutics, Inc. (PBLA) can sell. Click on Rating Page for detail.

The price of Panbela Therapeutics, Inc. (PBLA) is 0.3352 and it was updated on 2024-07-19 07:01:49.

Currently Panbela Therapeutics, Inc. (PBLA) is in undervalued.

News
    
News

Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript

  • Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants James Carbonara - IR, HaydenIR Jennifer Simpson - President & CEO Susan Horvath - CFO Conference Call Participants Jonathan Aschoff - Roth Capital Partners Operator Good afternoon, everyone, and welcome to the Panbela Therapeutics First Quarter 2024 Earnings Call. [Operator Instructions].
    Wed, May. 15, 2024

Panbela Provides Business Update and Reports Q1 2024 Financial Results

  • MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.
    Wed, May. 15, 2024

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

  • MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled “EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION”. These patents claim a novel composition of a fixed dose combination of eflornithine and sulindac, which is called Flynpovi.
    Mon, May. 06, 2024

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

  • MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024.
    Wed, May. 01, 2024

Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week

  • MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the Digestive Disease Week (DDW) conference, which will be held May 18-21, 2024. The work reflects the Company's on-going collaboration with Vanderbilt University Medical Center.
    Tue, Apr. 30, 2024
Transcripts
Transcipts Data
SEC Filings
SEC Filings

Panbela Therapeutics, Inc. (PBLA) - D

  • SEC Filings
  • 01/05/2024

Panbela Therapeutics, Inc. (PBLA) - D

  • SEC Filings
  • 11/17/2023

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 11/13/2023

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 11/13/2023

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 09/14/2023

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 03/29/2023

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 02/01/2023

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 10/06/2022

Panbela Therapeutics, Inc. (PBLA) - D

  • SEC Filings
  • 06/29/2022

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 06/27/2022

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 06/24/2022

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 09/15/2021

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 06/11/2021

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 05/27/2021

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 04/01/2021

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 12/03/2020

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 09/14/2020

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 09/09/2020

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 09/01/2020

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 07/17/2020

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 07/17/2020

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 06/26/2020

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 06/09/2020

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 05/27/2020

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 12/23/2019

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 12/20/2019

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 09/26/2019

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 09/24/2019

Panbela Therapeutics, Inc. (PBLA) - D

  • SEC Filings
  • 09/09/2019

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 09/04/2019

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 08/26/2019

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 08/26/2019

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 07/02/2019

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 05/23/2019

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 01/24/2019

Panbela Therapeutics, Inc. (PBLA) - D

  • SEC Filings
  • 01/04/2019

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 01/03/2019

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 10/01/2018

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 06/14/2018

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 05/29/2018

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 04/19/2018

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 04/19/2018

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 03/08/2018

Panbela Therapeutics, Inc. (PBLA) - D

  • SEC Filings
  • 03/06/2018

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 03/01/2018

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 02/22/2018

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 12/15/2017

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 03/29/2017

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 03/21/2017

Panbela Therapeutics, Inc. (PBLA) - D

  • SEC Filings
  • 03/06/2017

Panbela Therapeutics, Inc. (PBLA) - 5

  • SEC Filings
  • 02/14/2017

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 12/29/2016

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 12/29/2016

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 12/14/2016

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 12/01/2016

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 06/28/2016

Panbela Therapeutics, Inc. (PBLA) - D

  • SEC Filings
  • 06/27/2016

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 11/10/2015

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 10/13/2015

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 10/05/2015

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 09/14/2015

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 05/26/2015

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 05/26/2015

Panbela Therapeutics, Inc. (PBLA) - 4

  • SEC Filings
  • 05/19/2015

Panbela Therapeutics, Inc. (PBLA) - 3

  • SEC Filings
  • 05/15/2015
Press Releases
StockPrice Release
More Headlines
News

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

  • Trial's lower-than-expected event rate suggests improved survival outcomes Trial's lower-than-expected event rate suggests improved survival outcomes
  • 04/22/2024

Panbela Announces Poster Presentation at American Association for Cancer Research:

  • Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
  • 04/18/2024

Panbela Announces Transfer to OTCQB Market

  • MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved for quotation on the OTCQB market. Panbela's common stock will be eligible for quotation on the OTCQB starting on April 17, 2024, under the symbol “PBLA.”
  • 04/16/2024

Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript

  • Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
  • 03/26/2024

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

  • MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023. As previously announced, management is hosting earnings call today at 4:30 p.m. ET.
  • 03/26/2024

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

  • MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.
  • 03/12/2024

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

  • The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
  • 02/23/2024

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

  • MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares.
  • 02/15/2024

Panbela Announces Closing of Approximately $9.0 Million Public Offering

  • MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “Public Warrants”) at a purchase price of $2.06 per share and associated Public Warrants and $2.059 per pre-funded warrant and associated Public Warrants. The pre-funded warrants have an exercise price of $0.001 per share. The Public Warrants have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The Public Warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events.
  • 02/01/2024

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

  • MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024. The work reflects the Company's on-going collaboration with Johns Hopkins University School of Medicine.
  • 01/30/2024

Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?

  • Panbela Therapeutics (NASDAQ: PBLA ) stock is falling on Monday after the clinical-stage biopharmaceutical company revealed the pricing of a public offering for its shares. Panbela Therapeutics is selling 4,375,000 shares of its common stock for $2.06 each.
  • 01/29/2024

Panbela Announces Pricing of Approximately $9.0 Million Public Offering

  • MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “Common Warrants”) at a purchase price of $2.06 per share and associated Common Warrants. The Common Warrants will have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The Common Warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events. The offering is expected to close on or about January 31, 2024, subject to customary closing conditions.
  • 01/29/2024

Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

  • MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has reached 50% enrollment for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at  https://clinicaltrials.gov/ct2/show/NCT05254171  .
  • 01/25/2024

Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

  • A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma. A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma.
  • 01/18/2024

Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024

  • MINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will implement the previously announced and stockholder approved 1-for-20 reverse split of its common stock. The reverse stock split will be effective as of the morning of January 18, 2024, and the company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “PBLA.” The CUSIP number for the common stock following the reverse stock split will be 69833W404.
  • 01/16/2024

Panbela Therapeutics' stock tumbles, after more than tripling the past 2 days

  • Shares of Panbela Therapeutics Inc. PBLA, +55.45% dropped 21.7% in premarket trading, as they paused after a two-day “meme”-like rally of 243.5%. The two-day rally in the biopharmaceutical company's stock, which followed a record-low close of 45.7 cents on Friday, was fueled by positive news from the U.S. Food and Drug Administration regarding a treatment for child cancer.
  • 12/20/2023

Panbela Therapeutics' stock skyrockets after positive FDA news on child cancer treatment

  • Shares of Panbela Therapeutics Inc. skyrocketed again Tuesday, following positive news from the U.S. Food and Drug Administration regarding a treatment for child cancer.
  • 12/19/2023

Panbela Therapeutics, Inc. (PBLA) Q3 2023 Earnings Call Transcript

  • Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants James Carbonara - IR Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Greetings, and welcome to the Panbela Therapeutics Third Quarter 2023 Earnings Call. [Operator Instructions] Please note this conference is being recorded.
  • 11/10/2023

5 Hot Penny Stocks To Watch In The Stock Market Today

  • Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, understanding things like stock market news and events is important.
  • 10/25/2023

Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023

  • MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 9, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.
  • 10/24/2023

Panbela to Present at the LD Micro Investor Conference

  • MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced today that management will be presenting at the LD Micro Conference on Wednesday, October 4, 2023, at 3:30pm PT. The presentation will be streamed live and available for replay at: https://me23.sequireevents.com/ .
  • 09/19/2023

Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference

  • MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that management will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference.
  • 08/28/2023

Panbela Therapeutics, Inc. (PBLA) Q2 2023 Earnings Call Transcript

  • Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants James Carbonara - Investor Relations Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Greetings and welcome to the Panbela Therapeutics Second Quarter 2023 Earnings Call. [Operator Instructions] Please note this conference is being recorded.
  • 08/10/2023

Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023

  • MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 10, 2023, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023.
  • 07/31/2023

Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study

  • Panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data from a late-stage study of ivospemin in the treatment of pancreatic cancer.
  • 07/11/2023

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

  • The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
  • 07/05/2023

Panbela Therapeutics, Inc. (PBLA) Q1 2023 Earnings Call Transcript

  • Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - President & CEO Sue Horvath - VP & CFO Conference Call Participants Jonathan Aschoff - Roth MKM Operator Good day, and welcome to the Panbela Therapeutics first-quarter 2023 earnings call. [Operator Instructions].
  • 05/07/2023

Mastering the Best Penny Stock Swing Trading Techniques

  • Use these tips for swing trading penny stocks The post Mastering the Best Penny Stock Swing Trading Techniques  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 04/27/2023

Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023

  • MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 4, 2023, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2023.
  • 04/24/2023

Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

  • Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.
  • 04/13/2023

Panbela Therapeutics, Inc. (PBLA) Q4 2022 Earnings Call Transcript

  • Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good day, everyone. And welcome to the Panbela Therapeutics Fourth Quarter 2022 Earnings Call.
  • 03/16/2023

Panbela Therapeutics, Inc. (PBLA) Q3 2022 Earnings CallTranscripts

  • Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants James Carbonara - Hayden IR Jennifer Simpson - CEO Susan Horvath - CFO Conference Call Participants Tony Butler - ROTH Capital Operator Good day, and welcome to the Panbela Therapeutics Third Quarter 2022 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, James Carbonara.
  • 11/13/2022

Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results

  • MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA ), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 10, 2022, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2022.
  • 10/31/2022

Panbela Therapeutics, Inc.'s (PBLA) CEO Jennifer Simpson on Q2 2022 Results - Earnings Call Transcript

  • Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Tony Butler – ROTH Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
  • 08/15/2022

Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results

  • MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 15, 2022, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2022.
  • 08/01/2022

Panbela Therapeutics' (PBLA) CEO Jennifer Simpson on Q1 2022 Results - Earnings Call Transcript

  • Panbela Therapeutics Inc. (NASDAQ:PBLA ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants James Carbonara – Managing Partner-Hayden IR, Inc. Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Robin Garner – Craig-Hallum Tony Butler – Roth Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
  • 05/14/2022

Panbela Schedules Conference Call on May 12, 2022, to Report 2022 First Quarter Financial Results

  • MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on May 12, 2022 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2022.
  • 04/26/2022

Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q4 2021 Results - Earnings Call Transcript

  • Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q4 2021 Results - Earnings Call Transcript
  • 03/24/2022

Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results

  • MINNEAPOLIS, March 08, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on March 24, 2022 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2021.
  • 03/08/2022

Panbela Therapeutics Acquires Cancer Prevention Pharmaceuticals For Stock & Milestone Payment

  • Panbela Therapeutics Inc (NASDAQ: PBLA) has agreed to acquire a privately-held Cancer Prevention Pharmaceuticals Inc (CPP) for a combination of stock and future milestone payments. The combined entity will have an expanded pipeline addressing an estimated $5 billion market.
  • 02/22/2022

Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication

  • Data from phase 1b study using SBP-101 for patients with pancreatic cancer will be shown at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 20- 22, 2022. Pancreatic cancer patients in cohort 2 given SBP-101 + chemotherapies achieved ORR of 71%; Cohort 4 patients achieved ORR of 48% but median overall survival has not yet been reached.
  • 01/05/2022

Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q3 2021 Results - Earnings Call Transcript

  • Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q3 2021 Results - Earnings Call Transcript
  • 11/12/2021

Panbela Schedules Conference Call on November 10, 2021, to Report 2021 Third Quarter Financial Results

  • MINNEAPOLIS , Oct. 25, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc.  (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on November 10, 2021, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2021.
  • 10/25/2021

Panbela to Present at Upcoming Investor Conferences

  • MINNEAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will present at upcoming investor conferences:
  • 09/07/2021

Panbela Therapeutics, Inc. (PBLA) CEO Jennifer Simpson on Q2 2021 Results - Earnings Call Transcript

  • Panbela Therapeutics, Inc. (PBLA) CEO Jennifer Simpson on Q2 2021 Results - Earnings Call Transcript
  • 08/11/2021

Panbela Provides Business Update and Reports Q2 2021 Financial Results

  • MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provided a business update and reported financial results for the quarter ended June 30, 2021. Management is hosting an earnings call today at 4:30 p.m. ET.
  • 08/11/2021

Panbela to Present at Access to Giving Virtual Conference on July 15, 2021, at 10:30 a.m. ET

  • MINNEAPOLIS, July 07, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that the company will present at Access to Giving Virtual Conference. The presentation will be given by Panbela's President & Chief Executive Officer, Jennifer K. Simpson, PhD, MSN, CRNP.
  • 07/07/2021

PANBELA THERAPEUTICS ANNOUNCES CLOSING OF $10.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK

  • MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the “Company” or “Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the closing of its previously announced public offering of 3,333,334 shares of common stock of the Company at a price to the public of $3.00 per share, less underwriting discounts and commissions.
  • 07/02/2021

PANBELA THERAPEUTICS INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL OFFERING OF COMMON STOCK TO $10.0 MILLION

  • MINNEAPOLIS, June 30, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the “Company” or “Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 3,333,334 shares of common stock of the Company at a price to the public of $3.00 per share, less underwriting discounts and commissions. The closing of the public offering is expected to occur on or about July 2, 2021, subject to satisfaction of customary closing conditions.
  • 06/30/2021

PANBELA THERAPEUTICS ANNOUNCES $5.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK

  • MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the “Company” or “Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company at a price to the public of $3.00 per share, less underwriting discounts and commissions. The closing of the public offering is expected to occur on or about July 2, 2021, subject to satisfaction of customary closing conditions.
  • 06/29/2021

Panbela Set to Join Russell Microcap® Index

  • MINNEAPOLIS, June 08, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution effective after the US market opens on June 28, according to a preliminary list of additions posted June 4.
  • 06/08/2021

Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2021 ASCO Annual Meeting

  • MINNEAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced the presentation of interim clinical data from its Phase 1b combination therapy study of SBP-101, a proprietary polyamine analogue, with gemcitabine and nab-paclitaxel (G+A) in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDA), at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021.
  • 06/04/2021

Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q1 2021 Results - Earnings Call Transcript

  • Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q1 2021 Results - Earnings Call Transcript
  • 05/12/2021

Panbela Provides Business Update and Reports Q1 2021 Financial Results

  • MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today provides a business update and reports financial results for the quarter ended March 31, 2021. Management is hosting an earnings call today at 4:30 p.m. ET.
  • 05/12/2021

Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting

  • MINNEAPOLIS, April 06, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4-8, 2021.
  • 04/06/2021

Corrected: Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results

  • MINNEAPOLIS, March 26, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), is re-issuing this press release solely to correct an inadvertent decimal error in the net loss per share reported in the discussion under the heading “Fourth Quarter ended December 31, 2020 Financial Results.” All other data and disclosure remains unchanged.
  • 03/26/2021

Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results

  • MINNEAPOLIS, March 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business update and reports financial results for the quarter and full year ended December 31, 2020. Management is hosting an earnings call today at 4:30 p.m. ET.
  • 03/25/2021

Panbela Schedules Conference Call on March 25, 2021 to Report 2020 Fourth Quarter Financial Results

  • MINNEAPOLIS, March 17, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will host a conference call on March 25, 2021 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.
  • 03/17/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Panbela Therapeutics Inc. - PBLA

  • NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Panbela Therapeutics Inc. ("Panbela" or the "Company") (NASDAQ: PBLA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The...
  • 02/18/2021

Panbela Announces Research Agreement with Johns Hopkins University School of Medicine

  • MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a research agreement with the Johns Hopkins University School of Medicine. The collaboration is intended to focus on the further development of Panbela's investigative agent SBP-101, including activity in cell lines outside of pancreatic cancer, biomarkers informing diagnostics and potential combination with checkpoint inhibitors.
  • 02/10/2021

Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.

  • MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective December 2, 2020. The Company's trading symbol will also change from SNBP to PBLA at the opening of the markets on December 2, 2020. As a result of the change, the CUSIP number for the company's common stock will also change to 69833Q100. Stockholders are not required to exchange their existing share certificates or warrants for new certificates or warrants bearing the new name. The name change does not affect the company's capital structure or the rights of the company's stockholders, and no action is required by existing stockholders.
  • 12/01/2020
Unlock
PBLA Ratings Summary
PBLA Quant Ranking